8-K: Halozyme Raises 2026 Guidance, Boosts 2025 Estimates

Halozyme Therapeutics announced raised financial guidance for 2026 and updated preliminary 2025 estimates, alongside the acquisition of Surf Bio for its hyperconcentration technology.

Summary

• Halozyme Therapeutics, Inc. (HALO) provided preliminary unaudited financial estimates for the year ended December 31, 2025, and raised its full-year 2026 and multi-year financial guidance.
• The company acquired Surf Bio, Inc. in December 2025 for an upfront payment of $300 million and up to $100 million in contingent milestone payments, totaling up to $400 million.
• Surf Bio's hyperconcentration technology aims to enable high concentrations of up to 500 mg/mL for various therapeutics, including monoclonal antibodies and small molecules, for single auto-injector shots.
• Preliminary unaudited 2025 revenue is estimated to be in the range of $1,385 million to $1,400 million, representing a year-over-year growth of 36% to 38%.
• Preliminary unaudited 2025 royalty revenue is estimated between $865 million and $870 million, showing a year-over-year growth of 51% to 52%.
• Preliminary unaudited 2025 product sales are estimated between $372 million and $377 million.
• Preliminary unaudited 2025 collaboration revenue is estimated between $148 million and $153 million.
• For 2026, total revenue guidance was raised to $1,710 million to $1,810 million, an increase from the previous guidance of $1,430 million to $1,530 million.
• 2026 royalty revenue guidance was raised to $1,130 million to $1,170 million, up from $900 million to $940 million previously, projected to exceed $1 billion one year earlier than previously expected.
• Adjusted EBITDA guidance for 2026 was increased to $1,125 million to $1,205 million, including a new $60 million investment for Hypercon and Surf Bio.
• Non-GAAP diluted EPS guidance for 2026 was raised to $7.75 to $8.25, also including the $60 million investment for Hypercon and Surf Bio.
• In 2025, Halozyme expanded partnerships with three new ENHANZE collaboration and licensing agreements, one new auto-injector commercial licensing and supply agreement, and two auto-injector development agreements.
• Janssen gained global approvals for Rybrevant Faspro, marking the tenth ENHANZE-approved product.
• The company's strategic growth roadmap included the acquisitions of Elektrofi (Hypercon technology) and Surf Bio (hyperconcentration technology) in 2025, both with long-duration IP into the mid-2040s.

Sentiment

Score: 9

Explanation: The filing presents significantly positive news, including raised financial guidance for 2026, strong preliminary 2025 results, and a strategic acquisition that expands the company's drug delivery portfolio and extends its intellectual property horizon. The consistent growth in royalty revenue and the acceleration of key financial milestones indicate robust business performance and a strong future outlook.

Positives

• Raised 2026 financial guidance across all key metrics (Total Revenue, Royalty Revenue, Adjusted EBITDA, Non-GAAP Diluted EPS) indicates strong future performance expectations.
• Preliminary unaudited 2025 estimates show robust year-over-year growth: Total Revenue up 36% to 38% and Royalty Revenue up 51% to 52%.
• Royalty revenue is projected to exceed $1 billion in 2026, one year earlier than previously projected, demonstrating accelerated growth in the core ENHANZE business.
• The acquisition of Surf Bio and its hyperconcentration technology, along with Elektrofi's Hypercon technology, broadens the drug delivery portfolio and extends royalty horizons with long-duration IP into the mid-2040s.
• Expansion of new partnerships in 2025, including three new ENHANZE collaboration agreements and multiple auto-injector agreements, signifies continued demand for Halozyme's technologies.
• Janssen's global approval of Rybrevant Faspro as the tenth ENHANZE-approved product validates the technology's commercial success and market acceptance.
• Management expresses confidence in delivering durable revenue growth well into the 2040s and supporting long-term shareholder value.

Risks

• Actual results could differ materially from forward-looking statements due to market conditions and changes in domestic and foreign business.
• Changes in the competitive environment in which the company operates could impact financial performance.
• The expected benefits of the acquisitions of Elektrofi and Surf Bio may not materialize as anticipated.
• Unexpected early expiration or termination of patent terms for the company's drug delivery technologies could affect future royalty payments.
• Unexpected levels of revenues, expenditures, and costs could impact profitability.
• Unexpected results or delays in business growth, or in the development, regulatory review, or commercialization of partnered or proprietary products.
• Regulatory approval requirements may pose challenges or delays.
• Unexpected adverse events or patient outcomes could affect product adoption and market perception.
• Competitive conditions could intensify, impacting market share and pricing power.

Future Outlook

Halozyme projects continued strong growth, with royalty revenue expected to exceed $1 billion in 2026, one year ahead of schedule. By the end of 2026, the company anticipates having 15 partner programs in development and signing three or more new drug delivery licensing agreements. The strategic acquisitions of Elektrofi and Surf Bio are expected to broaden the drug delivery portfolio, amplify and extend royalty horizons, and diversify value creation pathways, reinforcing confidence in durable revenue growth well into the 2040s.

Management Comments

• "Our increased multi-year guidance reflects both the strength of our core ENHANZE business and the exceptional momentum we built in 2025."
• "In 2025, we expect royalty revenue growth to exceed 50% yearoveryear, a clear demonstration of the strength of our business model and the durable demand for ENHANZEenabled products globally."
• "Our operational accomplishments and acquisitions broaden our drug delivery portfolio and opportunity, amplify and extend our royalty horizons, and diversify the pathways through which we create value."
• "In the near-term, our strong 2026 total revenue expectations of 23% to 30% yearoveryear growth underscore the strength of our royalty revenue, which is projected to exceed $1 billion in 2026, growing at 30% to 35% versus prior year. This is one year earlier than previously projected."
• "By the end of 2026, we project we will have 15 partner programs in development and have signed three or more new drug delivery licensing agreements, expanding the reach and growing our opportunity through our diversified drug delivery portfolio."
• "Taken together, these drivers reinforce our confidence in delivering durable revenue growth well into the 2040s and support our conviction in Halozymes longterm growth profile which will deliver sustained value for shareholders."

Industry Context

Halozyme's focus on drug delivery technologies, particularly subcutaneous administration and hyperconcentration, aligns with a broader industry trend towards improving patient convenience, reducing treatment burden, and expanding the applicability of complex biologics. The acquisition of Surf Bio and its technology for high-concentration formulations addresses a critical need in the biopharmaceutical sector to enable at-home or in-HCP office use for a wider range of therapies, potentially increasing patient adherence and market access for partner products. The continued expansion of ENHANZE partnerships and product approvals, like Janssen's Rybrevant Faspro, demonstrates the ongoing demand for innovative drug delivery solutions in the competitive biologics market.

Comparison to Industry Standards

• The company's ENHANZE technology, with 10 commercialized products across over 100 global markets and licenses to leading pharmaceutical and biotechnology companies (e.g., Roche, Takeda, Pfizer, Janssen), sets a high standard for commercially validated subcutaneous drug delivery solutions.
• The acquisition of Surf Bio's hyperconcentration technology, aiming for up to 500 mg/mL for single auto-injector shots, positions Halozyme at the forefront of developing advanced drug formulation and delivery methods, potentially surpassing current industry capabilities for high-volume subcutaneous injections.
• The projected royalty revenue growth exceeding 50% year-over-year in 2025 and 30-35% in 2026, with royalty revenue expected to surpass $1 billion in 2026, demonstrates a robust and accelerating revenue stream that is highly competitive within the biopharmaceutical licensing and royalty-based business models.

Stakeholder Impact

• Shareholders: Positive impact due to raised financial guidance, strong growth projections, strategic acquisitions, and management's confidence in long-term value creation.
• Patients: Potential for improved treatment experiences and outcomes through expanded and more convenient drug delivery options (e.g., high-concentration subcutaneous injections for at-home use).
• Partners: Strengthened collaboration opportunities and enhanced drug delivery solutions for their therapeutic products, potentially leading to broader market access and patient adoption.
• Employees: Potential for growth and expansion within the company due to strategic acquisitions and increased business activity.

Next Steps

• Completion and finalization of the company's financial and accounting close procedures for the year ended December 31, 2025.
• Filing of the Company's Form 10-K for the year ended December 31, 2025 with the Securities and Exchange Commission.
• Continued development of 15 partner programs by the end of 2026.
• Signing of three or more new drug delivery licensing agreements by the end of 2026.

Key Dates

Recommendation

The filing indicates a strong 'strong buy' recommendation. Halozyme has significantly raised its financial guidance for 2026 across all key metrics, including total revenue, royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS. The preliminary 2025 results show exceptional year-over-year growth, particularly in royalty revenue, which is now expected to exceed $1 billion a year earlier than projected. The strategic acquisition of Surf Bio, coupled with the earlier Elektrofi acquisition, expands the company's proprietary drug delivery technology portfolio with long-duration intellectual property, securing future revenue streams. These factors demonstrate robust operational momentum, strong market demand for its ENHANZE technology, and a clear path for sustained long-term growth and shareholder value creation, making it a highly attractive investment.

Keywords

Halozyme Therapeutics, HALO, ENHANZE, Drug Delivery, Hyperconcentration Technology, Surf Bio, Biologics, Subcutaneous Delivery, Financial Guidance, Royalty Revenue, Adjusted EBITDA, Non-GAAP EPS, Biopharmaceutical, Acquisition, Biotech